This high-flying biotech is trading on the cheap....…
Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
8-K...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CNBC's Brian Sullivan highlights the stocks seeing the most insider buying this week, on Worldwide Exchange, including names like Hanes…
Parini, Michael - Vorstand - Tag der Transaktion: 2020-11-04...…
Todays Daily Dose brings you news about FDAs briefing information related to Biogens Alzheimers drug candidate ahead of the panel…
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and…
What will the drugmaker do once it has the cystic fibrosis market cornered?...…
10-Q...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020....…
VRTX earnings call for the period ending September 30, 2020....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) decreased 1.4% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased…
These two rare-disease drug developers are experts at penetrating their markets....…
The biotech sector was in focus as Biogens (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regenerons (REGN) Ebola…
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity...…
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co...…
Is (VRTX) Outperforming Other Medical Stocks This Year?...…
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as…
Vertex Pharmaceuticals (VRTX) closed at $220.51 in the latest trading session, marking a +1.11% move from the prior day....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär":
Thomas Bergmann, Redakteur beim Anlegermagazin "Der Aktionär", nimmt die Aktie des US-Biotechkonzerns Vertex…
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Thursday on news that Vertex Pharmaceuticals discontinued its trial of a…
Vertex (VRTX) could produce exceptional returns because of its solid growth attributes....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Investors are concerned about Vertexs pipeline after a rare miss in the clinic....…
Todays Daily Dose brings you news about AnaptysBios generalized pustular psoriasis trial results, Cyclerion discontinuing its Sickle Cell Disease drug…
Vertex Pharmaceuticals Inc. VRTX stock fell in the extended session Wednesday after the biotech company said it would stop developing…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $276.09, marking a +0.54% move from the previous day....…
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $265.82, marking a +1.85% move from the previous day....…
The biotech company is up more than 23% in 2020, but where will it be in five years?...…
Is (VRTX) Outperforming Other Medical Stocks This Year?...…
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $270.31, moving +0.96% from the previous trading session....…
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) kündigte heute an, dass Daten aus dem Unternehmensportfolio von Medikamenten gegen Mukoviszidose (Cystic Fibrosis,…
Vertex Pharmaceuticals (VRTX) closed at $264 in the latest trading session, marking a -0.52% move from the prior day....…
8-K...…
Biotech-Aktien zeigten sich im deutschen Handel durchwachsen. Unter anderem stiegen MorphoSys leicht. An der Wall Street dominieren negative …
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertexs (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency....…
NEW YORK , Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL,…
Vertex Pharmaceuticals (VRTX) closed at $257.96 in the latest trading session, marking a +0.9% move from the prior day....…
The cystic fibrosis treatment specialist says it will submit a supplemental New Drug Application for Trikafta this year....…
The pharma giant controls a massive addressable market and has proven its ability to increase drug sales....…
The biopharmaceutical company is expensive, but its drugs recent sales make the company an alluring option....…